logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience says close to winning new patent for its flagship DehydraTECH technology

The group has received a Notice of Allowance from the US Patent and Trademark Office for a new patent to protect the use of its technology in mix-and-serve beverage formats

Lexaria Bioscience Corp. - Lexaria Bioscience Corp receives Notice of Allowance from US Patent and Trademark Office for a new patent to provides additional patent claims to protect its DehydraTECH technology
Lexaria also has issued stock options to purchase of up to 2,538,000 common shares at US$0.32 apiece

Lexaria Bioscience Corp (CSE:LXX) (OTCQX:LXRP) has revealed that it is close to winning a new patent for its flagship DehydraTECH technology. 

The company announced Thursday that it has received a Notice of Allowance from the US Patent and Trademark Office for a new patent which provides additional patent claims that protect the use of the DehydraTECH technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix-and-serve beverage formats.

“This signifies another addition to Lexaria's first patent family, under which eight US patents have previously been granted,” the British Columbia-based company said in a statement.

READ: Lexaria Bioscience joins fight against coronavirus as it files new US patent for drug delivery technology

The company said the patent application, titled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof," is expected to lead to the formal granting of the new patent within roughly 100 days or less.

DehydraTECH turns cannabis and hemp oils into stabilized powders, which allows for faster absorption into the human bloodstream.

In other company news, Lexaria said it has issued 2,538,000 stock options to certain employees, consultants, directors and officers for the purchase of up to 2,538,000 common shares at US$0.32 apiece. 

In addition, Lexaria is granting 700,000 stock options to an executive officer who also holds over 10% of the company's issued share capital for the purchase of up to 700,000 common shares at US$0.34 apiece.

The options are being issued under the company's shareholder approved Equity Incentive Plan whereby the exercise price of any options issued to a person holding 10% or more of the company's issued share capital must be equal to 110% of the fair market value of the company's shares. 

The options are exercisable for a period of five years expiring on April 23, 2025, with some issuances being subject to certain vesting provisions. The option shares will be subject to a four-month hold period as prescribed by Canadian Securities Exchange policies.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Lexaria Bioscience Corp.

Price: 0.53 CAD

CSE:LXX
Market: CSE
Market Cap: $47.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lexaria Bio Science and partner Altria complete Phase One of the development...

Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures. Bunka says everything went as planned and...

2 weeks, 4 days ago

2 min read